血清高敏C反应蛋白和白蛋白在SLE患者预后评估中的作用

摘要

Objective:To study the value of hsCRP and Alb in evaluating the prognosis of patients with systemic lupus erythematosus (SLE).Methods:126 SLE patients from January 2011 to January 2016 were enrolled in this study,and their clinical data were collected,including SLEDAI,hsCRP and Alb and complications.The correlation between hsCRP/Alb ratio and SLEDAI after treatment was analyzed.All patients were followed up after discharge,and the prognosis-related factors were analyzed.Results:After treatment,hsCRP/Alb ratio of patients with SLEDAI 10-14 score was significantly higher than that of 5-9 and 0-4 score (P ≤ 0.05).hsCRP/AIb ratio was positively correlated with infection (r =0.574),renal damage (r =0.499) and cardiac injury (r =0.516) (P ≤ 0.05),while it demonstrated no correlation with blood system damage,CNS damage and lung injury (P ＞ 0.05).after treatment SLEDAI ≥ 10 score,hsCRP/Alb ≥0.05 mg/g and complications significantly correlated with prognosis of patients (P ≤ 0.05).Conclusion:hsCRP/Alb correlates with the prognosis of patients with SLE at a certam level.%目的:研究高敏C反应蛋白(hsCRP)及白蛋白(Alb)比值(hsCRP/Alb)在系统性红斑狼疮(SLE)患者预后评估中的作用.方法:选取2011年1月-2016年1月期间本院收治的126例SLE患者,收集患者临床资料:包括治疗前后的SLE疾病活动指数评分(SLEDAI)、hsCRP和Alb水平及治疗过程中并发症的发生情况,分析hsCRP和Alb比值与治疗后SLEDAI及并发症的相关性.所有患者出院后均接受随访,分析患者预后的相关因素.结果:治疗后10-14分患者的hsCRP/Alb比值高于5-9分者及0-4分者,差异具有统计学意义(P≤0.05).hsCRP/Alb比值与患者的感染(r =0.574),肾脏损害(r =0.499)及心脏损害(r =0.516)的发生呈正相关(P≤0.05),与血液系统损害、中枢神经系统损害及肺损害的发生无显著相关性(P＞0.05).治疗后SLEDAI≥10、hsCRP/Alb≥0.05 mg/g及住院期间并发症是患者预后的相关因素(P≤0.05).结论:hsCRP/Alb与SLE患者的预后具有一定的相关性.